Palvella Therapeutics (PVLA) Accounts Payables (2013 - 2026)
Palvella Therapeutics (PVLA) reported Accounts Payables of $5.4 million for Q1 2026, up 22.56% year-over-year from $4.4 million in Q1 2025, and up 18.45% on a QoQ basis from $4.6 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of Accounts Payables data on file, last reported at $5.4 million in Q1 2026.
- Quarterly Accounts Payables rose 22.56% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (up 22.56% YoY) and the FY2025 annual result came in at $4.6 million, changed 0.2% from the prior year.
- Accounts Payables advanced to $5.4 million in Q1 2026 per PVLA's latest filing, from $4.6 million in the prior quarter.
- Across five years, Accounts Payables topped out at $14.1 million in Q1 2022 and bottomed at $801000.0 in Q3 2024.
- The 5-year median for Accounts Payables is $4.4 million (2025), against an average of $4.7 million.
- Peak annual rise in Accounts Payables reached 389.96% in 2024, while the deepest fall reached 87.26% in 2024.
- Tracing PVLA's Accounts Payables over 5 years: stood at $4.2 million in 2022, then sank by 77.47% to $936000.0 in 2023, then soared by 389.96% to $4.6 million in 2024, then rose by 0.2% to $4.6 million in 2025, then gained by 18.45% to $5.4 million in 2026.
- Per Business Quant, the three latest PVLA Accounts Payables figures stand at $5.4 million (Q1 2026), $4.6 million (Q4 2025), and $3.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 5.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.44 Mn |
| Dec 31, 2025 | 4.60 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 4.56 Mn |
| Mar 31, 2025 | 4.44 Mn |
| Dec 31, 2024 | 4.59 Mn |
| Sep 30, 2024 | 801,000.00 |
| Jun 30, 2024 | 969,000.00 |
| Mar 31, 2024 | 1.52 Mn |
| Dec 31, 2023 | 936,000.00 |
| Sep 30, 2023 | 2.82 Mn |
| Jun 30, 2023 | 7.60 Mn |
| Mar 31, 2023 | 5.83 Mn |
| Dec 31, 2022 | 4.15 Mn |
| Sep 30, 2022 | 3.64 Mn |
| Jun 30, 2022 | 10.79 Mn |
| Mar 31, 2022 | 14.08 Mn |
| Dec 31, 2021 | 8.61 Mn |
| Sep 30, 2021 | 19.69 Mn |
| Jun 30, 2021 | 2.31 Mn |
| Mar 31, 2021 | 3.47 Mn |
| Dec 31, 2020 | 7.73 Mn |
| Sep 30, 2020 | 7.49 Mn |
| Jun 30, 2020 | 5.94 Mn |
| Mar 31, 2020 | 6.94 Mn |
| Dec 31, 2019 | 9.94 Mn |
| Sep 30, 2019 | 5.44 Mn |
| Jun 30, 2019 | 8.49 Mn |
| Mar 31, 2019 | 3.73 Mn |
| Dec 31, 2018 | 3.35 Mn |
| Sep 30, 2018 | 2.69 Mn |
| Jun 30, 2018 | 4.56 Mn |
| Mar 31, 2018 | 6.58 Mn |
| Dec 31, 2017 | 6.17 Mn |
| Sep 30, 2017 | 2.60 Mn |
| Jun 30, 2017 | 4.65 Mn |
| Mar 31, 2017 | 3.32 Mn |
| Dec 31, 2016 | 3.72 Mn |
| Sep 30, 2016 | 4.52 Mn |
| Jun 30, 2016 | 1.64 Mn |
| Mar 31, 2016 | 1.71 Mn |
| Dec 31, 2015 | 1.06 Mn |
| Sep 30, 2015 | 1.12 Mn |
| Jun 30, 2015 | 2.06 Mn |
| Mar 31, 2015 | 1.54 Mn |
| Dec 31, 2014 | 1.26 Mn |
| Sep 30, 2014 | 650.00 |
| Jun 30, 2014 | 650.00 |
| Dec 31, 2013 | 278,008.00 |